Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe

All Our Peptide Articles

Complete guides, comparisons and scientific analyses on peptides in skincare, health and biohacking.

215 Articles
NAD+ Injections: What the Research Shows and Does Not Show
Science 20 November 2026

NAD+ Injections: What the Research Shows and Does Not Show

Most human NAD+ trials test oral precursors. The published data on injected NAD+ remain scarce, small, and mostly uncontrolled.

GLP-1 and Muscle Loss: What the Body Composition Data Actually Show
Health November 19, 2026

GLP-1 and Muscle Loss: What the Body Composition Data Actually Show

A detailed, source-by-source look at lean mass changes in the semaglutide and tirzepatide trials, what DXA and MRI can and cannot tell us, and why strength data matter more than scan numbers.

Stopping a GLP-1: What the Withdrawal Trials Show About Weight Regain
Health November 20, 2026

Stopping a GLP-1: What the Withdrawal Trials Show About Weight Regain

A factual review of the STEP 1 extension, STEP 4 and SURMOUNT-4: how much weight returned, how quickly, and what happened to cardiometabolic markers once the medication was withdrawn.

Biotinoyl Tripeptide-1: What This Cosmetic Peptide Is, and What the Evidence Actually Supports
Skincare November 19, 2026

Biotinoyl Tripeptide-1: What This Cosmetic Peptide Is, and What the Evidence Actually Supports

A neutral look at biotinyl-GHK, the peptide sold inside Procapil, separating manufacturer claims, in vitro work, and published human studies.

Collagen for Weight Loss: Does the Human Evidence Support It?
Health November 18, 2026

Collagen for Weight Loss: Does the Human Evidence Support It?

A straight answer first, then a close look at the small number of randomized trials that measured body fat, fat-free mass and appetite, and at what those trials still cannot tell us.

Melanotan Side Effects: Reported Reactions, Skin Changes and What the Case Reports Really Show
Health 17 November 2026

Melanotan Side Effects: Reported Reactions, Skin Changes and What the Case Reports Really Show

A neutral, evidence-based safety review of melanotan I, melanotan II, and afamelanotide, the one melanocortin analogue that regulators have actually authorized.

Tesamorelin Side Effects: What the Approved Label and the Pivotal Trials Actually Report
Health 18 November 2026

Tesamorelin Side Effects: What the Approved Label and the Pivotal Trials Actually Report

A source-based review of adverse reactions, IGF-1 elevation, glucose monitoring and contraindications in the population where tesamorelin was studied: adults living with HIV who have lipodystrophy.

KPV Side Effects: What Is Known, and What Is Not
Health November 17, 2026

KPV Side Effects: What Is Known, and What Is Not

A neutral review of the safety evidence behind the tripeptide Lys-Pro-Val, where that evidence comes from, and why the gaps matter more than the reassurances.

Peptide Black Friday 2026: Verified Deals Only
Where to Buy November 13, 2026

Peptide Black Friday 2026: Verified Deals Only

Vendor codes we tested on a real cart, a daily price tracker that compares each price with its 30-day low, and the Peptide Lab offer.

Epitalon Prescription in the United States: Not Approved, Compounded Only Under Conditions
Guide November 12, 2026

Epitalon Prescription in the United States: Not Approved, Compounded Only Under Conditions

Epitalon has no FDA approval. Since the HHS enforcement discretion policy of October 28, 2026, a state-licensed pharmacy, a federal facility or a licensed physician may compound epitalon acetate for injection, but only if every listed condition is met.

KPV Prescription in the United States: What the HHS Compounding Policy Actually Says
Guide 11 November 2026

KPV Prescription in the United States: What the HHS Compounding Policy Actually Says

KPV has no FDA approval. Since October 2026, a narrow and temporary federal enforcement policy describes when a licensed US pharmacy or physician may compound KPV acetate for a named patient.

Semax Prescription in the United States: What the HHS Enforcement Discretion Policy Actually Says
Guide November 11, 2026

Semax Prescription in the United States: What the HHS Enforcement Discretion Policy Actually Says

Semax is not an FDA approved drug. Since October 28, 2026, HHS has said it does not intend to act against certain compounders who prepare it under a narrow set of conditions. Here is the exact scope of that statement.